» Articles » PMID: 24566564

Alopecia Areata: News on Diagnosis, Pathogenesis and Treatment

Overview
Date 2014 Feb 26
PMID 24566564
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

This review focuses on recent changes in the clinical, pathogenetic and therapeutic developments with regards to Alopecia Areata. Some new clinical forms and some phenomena have been described for the first time in recent years. Several phenomena previously observed such as the Renbok, the Koebner and the possibility that an exclamation mark hair can resume its physiological growth have been confirmed. The pathogenetic role of cytotoxic cells is increasingly evident, as well as the deficit of cells and the factors regulating the autoimmune response. The concept of immune privilege of the hair follicle has had further confirmation and have been identified some of the molecular mechanisms such as the expression of the receptors for killer lymphocytes on the trichokeratinocytes of the Outer Root Sheat. There is a renewed interest on the possible role of mast cell as a key element in the acute and chronic phases of the disease. New therapies are focused on the inhibition of the killer cells directed against antigens not yet fully specified of the hair follicle and on the restoration of the immune privilege of this structure. Alopecia Areata is a disease with high emotional impact, able to reduce the quality of life of patients and their family entourage. It is often frustrating for those affected and for the therapists due to its evolution quite unpredictable and the mixed response to the few validated therapies. Investment in research originate almost exclusively from voluntary associations of patients, which need to be known and supported.

Citing Articles

Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.

Huang J, Qian P, Tang Y, Li J, Liu F, Shi W Acta Derm Venereol. 2023; 103:adv12425.

PMID: 38112208 PMC: 10753592. DOI: 10.2340/actadv.v103.12425.


Association of Alopecia Areata with Sensorineural Hearing Loss: A Systematic Review and Meta-analysis.

Lien K, Ger T, Chi C Dermatology. 2023; 239(4):523-532.

PMID: 37094565 PMC: 10407832. DOI: 10.1159/000530784.


Expression of Long Noncoding RNA, HOTAIR, and MicroRNA-205 and Their Relation to Transforming Growth Factor β in Patients with Alopecia Areata.

Mohamad N, Khedr A, Shaker O, Hassan M Skin Appendage Disord. 2023; 9(2):111-120.

PMID: 36937162 PMC: 10015650. DOI: 10.1159/000527851.


Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis.

Chanprapaph K, Pomsoong C, Kositkuljorn C, Suchonwanit P Drug Des Devel Ther. 2022; 16:107-116.

PMID: 35027820 PMC: 8752075. DOI: 10.2147/DDDT.S342179.


A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.

Dillon K Clin Cosmet Investig Dermatol. 2021; 14:691-714.

PMID: 34211288 PMC: 8242127. DOI: 10.2147/CCID.S309215.